Sökning: "neutropenia"
Visar resultat 1 - 5 av 37 avhandlingar innehållade ordet neutropenia.
1. Model-Based Optimization of Clinical Trial Designs
Sammanfattning : General attrition rates in drug development pipeline have been recognized as a necessity to shift gears towards new methodologies that allow earlier and correct decisions, and the optimal use of all information accrued throughout the process. The quantitative science of pharmacometrics using pharmacokinetic-pharmacodynamic models was identified as one of the strategies core to this renaissance. LÄS MER
2. Rituximab-induced neutropenia : clinical and patophysiological studies
Sammanfattning : Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lymphocytes. It was originally developed for treatment of lymphomas as a targeted therapy against CD20 positive non-Hodgkin lymphomas (NHL). More recently, its use has expanded into patients with rheumatic diseases. LÄS MER
3. Bacteremia in patients with hematological malignancies and neutropenia
Sammanfattning : For hematological cancer patients, the risk of blood stream infection by bacterial pathogens is increased. Studies on pathogen panorama, efficacy of antimicrobial prophylaxis and antimicrobial resistance are important efforts to decrease morbidity, mortality and the risk of delays or reduction of intensity in cancer treatment. LÄS MER
4. Pharmacometric Models for Biomarkers, Side Effects and Efficacy in Anticancer Drug Therapy
Sammanfattning : New approaches quantifying the effect of treatment are needed in oncology to improve the drug development process and to enable treatment optimization for existing therapies. This thesis focuses on the development of pharmacometric models for biomarkers, side effects and efficacy in order to identify predictors of clinical response in anti-cancer drug therapy. LÄS MER
5. Etiology and risk factors of febrile neutropenia in children during cancer treatment
Sammanfattning : Side effects due to chemotherapy is still a major issue during cancer treatment. Febrile neutropenia and associated microbiological defined infections (MDIs) are dreaded complications, and still a cause of death during pediatric cancer treatment. LÄS MER